Syntiron is a US-based vaccine research and development company with a strong track record of developing patentable vaccine technology for humans that leverages bacterial metal receptors as immunological targets. Syntiron’s Alloy vaccine platform enables rapid design of highly cross-protective and dynamically immunogenic protein vaccines to combat a wide range of bacteria, including AMR pathogens. The Alloy vaccines are strong, broadly protective, and easy to make. The lead program, Alloy-UTI, targets urinary tract infections caused by several multidrug resistant gram-negative bacteria. UTIs are responsible for more antimicrobial use globally than any other human disease, so a vaccine will protect patients, lower healthcare costs, and reduce the use of antimicrobials in order to extend their utility to protect against other infections.